SHEET 1 OF 5

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOC ELITRA.0
011	IDDI CMENTAL	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. Unknown	S. PTO
APPLICANT Zyskind, et al.		% U
FILING DATE Herewith	GROUP Unknown	310

	U.S. PATENT DOCUMENTS								
EXAMINE		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)		
	1	4,622,297	11/11/86	Kappner, et al.					
	2	4,980,281	12/25/90	Housey, et al.					
	3	5,190,931	03/02/93	Inouye					
	4	5,208,149	05/04/93	Inouye, et al.					
	.5	5,266,464	11/30/93	Housey, et al.	0 0		P		
	6	5,272,065	12/21/93	Inouye, et al.					
	7	5,569,588	12/09/96	Ashby, et al.					
	8	5,585,277	12/17/96	Bowie, et al.					
	9	5,688,655	11/08/97	Housey, et al.					
	10	5,756,305	05/26/98	Timberlake, et al.					
	11	5,821,076	10/13/98	Timberlake, et al.					
	12	5,877, 007	03/02/99	Housey, et al.					
	13	5,965,352	10/12/99	Stoughton, et al.					
	14	6,015,669	01/18/00	Holden					
	15	6,174,678	01/16/01	Menzel, et al.					

,	FOREIGN PATENT DOCUMENTS								
EXAMINER		DOCUMENT NUMBER	DATE	DATE COUNTRY CLASS SUBCLAS		SUBCLASS	TRANSLATION		
INITIAL							YES	NO	
$\bigcirc$	16	WO 95/06132	03/02/95	PCT			·		
	17	WO 96/23075	08/01/96	РСТ					
7	18	WO 96/40979	12/19/96	РСТ					
	19	WO 97/11690	04/03/97	РСТ					
	20	WO 97/23642	07/03/97	PCT					
	21	WO 97/42210	11/13/97	РСТ					
	22	WO 98/03533	01/29/98	РСТ					
	23	WO 99/23244	05/14/99	РСТ					
	24	WO 99/36554	07/22/99	РСТ					

EXA	MI	NEF
-----	----	-----

DATE CONSIDERED

1.7.03

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

(USE SEVERAL SHEETS IF NECESSARY)

BY APPLICANT

ATTY, DOCKET NO. ELITRA.001DV1	APPLICATION NO. Unknown
APPLICANT	

Zyskind, et al.	
FILING DATE	GROUP
Herewith	Unknown

	FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	TRANSLATION	
INITIAL							YES	NO	
()a	25	WO 99/43338	09/02/99	PCT					
91	26	WO 99/49888	10/07/99	PCT					
							•		

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
7n	27	Austin, A. E., et al., Journal of Bacteriology, 172:5312-5325, 1990,
41		"Genetic Analysis of Lipopolysaccharide Core Biosynthesis by Escherichia coli k12 Insertion Mutagenesis of the RFA Locus."
	29	Lee, N. G., et al., Infection and Immunity., 63(3):818-824, 1995,
)		"Molecular Cloning and Characterization of the Nontypable Haemophilus Influenzae-2019 rfaE Gene Required for Lipopolysaccharide Biosynthesis."
	30	Valvano, M. A., et al., Journal of Bacteriology, 182:488-497, 2000, "The rfaE Gene from Escherichia coli Encodes a Bifunctional Protein Involved
$  \wedge \rangle$		in Biosynthesis of the Lipopolysaccharide Core Precursor ADP-L-glycero-D-manno-heptose."
X	31	Van Heeswijk, W. C., et al., Molecular Microbiology, 9:443-457, 1993,
(y		"The Genes of the Glutamine Synthetase Adenylylation Cascade are not Regulated by Nitrogen in Escherichia coli."
		·

EXAMINER	DATE CONSIDERED	1-7.03

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

ATTY, DOCKET NO. ELITRA.001DV1	APPLICATION NO. Unknown
W	
ADDITIONAL	

Zyskind, et al.

FILING DATE GROUP
Herewith Unknown

	U.S. PATENT DOCUMENTS							
	IINER QAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
		32	4,906,742	3/6/90	Young et al.			
	/	33	5,679,523	10/21/97	Li et al.			
		34	5,846,772	12/8/98	Hodgson et al.		_	
		35	5,854,020	12/29/98	Hodgson et al.			
		36	5,858,709	-1/12/99	Hodgson et al.			
		37	5,869,290	2/9/99	Freeman et al.			
		38	5,882,643	3/16/99	Lonetto			
•		39	5,885,572	3/23/99	Gentry e t al.			, , , , , , , , , , , , , , , , , , , ,
		40	5,891,667	4/6/99	Hodgson et al.			
		41	5,910,414	6/8/99	Gwynn et al.			2
		42	5,955,275	9/21/99	Kamb			
	2.	43	6,020,121	2/1/00	Bao et al.			
		44	6,037,123	3/14/00	Benton et al.			

				FOREIGN PATENT DOCUMENTS				
EXAMINE	R	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL							YES	NO
$\bigcap$	45	0816511 A1	1/7/98	EP				
9	46	0837142 A1	4/22/98	EP				
	47	0891984 A2	1/20/99	EP				
	48	0889123 A2	1/7/99	EP				
	49	0889129 A2	1/7/99	EP				
	50	0892056 A2	1/20/99	EP				
	51	0892064 A2	1/20/99	EP				
	52	0894806 A1	2/3/99	EP				
<b></b>	53	0897008 A2	2/17/99	EP				

EXAMINER (	1		DATE CONSIDERED	1-	7.	b 2	)
	í	<del></del>					

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

		STILL TO
ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. Unknown	
APPLICANT Zyskind, et al.		
FILING DATE Herewith	GROUP Unknown	

				FOREIGN PATENT DOCUMENTS				
EXAMINER	DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL							YES	NO
7	54	0906959 A2	4/7/99	EP				
	55	0905247 A2	3/31/99	EP			•	
	56	0900845 A2	3/10/99	EP .			,	
	57	WO 97/16177	5/9/97	РСТ				
	.58	.WO.97/27212	.7/31/97	PCT				
	59	WO 97/48822	12/24/97	PCT		4:		
	60	WO 98/44135	10/8/98	PCT				
	61	WO 97/40851	11/6/97	РСТ				
	62	WO 97/37026	10/9/97	PCT				
	63	WO 98/20161	5/14/98	РСТ	Ì		·	
	64	WO 98/19162	5/7/98	РСТ				
	65	WO 99/28508	6/10/99	РСТ				
	66	WO 99/35494	7/15/99	РСТ				
	67	WO 99/50462	10/7/99	РСТ				
	68	WO 99/52926	10/21/99	РСТ				
	69	WO 99/53079	10/21/99	РСТ				
	70	WO 99/06839	2/11/99	РСТ				
	71	WO 99/61452	12/2/99	РСТ				
	72	WO 9929837	6/17/99	РСТ				
	73	WO 99/27128	6/3/99	РСТ				
	74	WO 99/27074	6/3/99	PCT				
	75	WO 99/26651	6/3/99	PCT				
1	76	WO 99/55729	11/4/99	PCT				
	77	WO 97/272213	7/31/97	PCT				
	78	WO 00/34481	6/15/00	PCT				
	79	WO 98/42854	10/1/98	PCT				
	80	WO 99/02673	1/21/99	PCT				
<del>/                                      </del>	81		5/22/98	PCT				
V	کے	WO 98/21366	3/22/98			<u> </u>		

EXAMINER DAT

DATE CONSIDERED

. 7.03

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. Unknown
APPLICANT Zyskind, et al.	
FILING DATE Herewith	GROUP Unknown

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	82	Armstrong, K.A. and Fan, D.P., "Essential Genes in the metB-malB Region of Escherichia coli K12," J. BACTERIOL. 126: 48-55 (1975).
	83	Biswas, E.E. and Biswas, S.B., "Mechanism and DnaB Helicase of <i>Escherichia coli</i> : Structural Domains Involved in ATP Hydrolysis, DNA Binding, and Oligomerization," BIOCHEM. 38:10919-10928 (1999).
	84	Blattner, et al., "The Complete Genome Sequence of Escherichia Coli K-12," SCIENCE 277:1453-1474 (1997).
	85	den Hollander, J.G., et al., "Synergism Between Tobramycin and Ceftazidime Against a Resistant Pseudomonas Aeruginosa Strain, Tested in an In Vitro Pharmacokinetic Model," ANTIMICROBIA AGENTS & CHEMOTHERAPY 41:95-110 (1997).
	86	Fukuoka, T., et al., "Combination Effect Between Panipenem and Vancomycin on Highly Methicillin-Resistant Staphylococcus Aureus," JAPAN. J. ANTIBIO. 50:411-419 (1997).
	87	Gabryelewicz, A., et al., "Multicenter Evaluation of Dual-Therapy (Omeprazol and Amoxycillin) for <i>Helicobacter Pylori</i> -Associated Duodenal and Gastric Ulcer (Two Years of the Observation)," J. PHYSIOL. PHARMACOL. 48 Suppl. 4:93-105 (1997).
		Gudkov, A.V., and Roninson, I.B., "Isolation of Genetic Suppressor Elements (GSEs) from Random Fragment cDNA Libraries in Retroviral Vectors," METHODS IN MOLEC. BIOL., Vol. 69 cDNA Library Protocols, Edited by I.G. Cowell and C.A. Austin, Humana Press, Inc., Totowa, N.Y.
	89	Gutmann, L., et al., "Involvement of Pencillin-Binding Protein 2 with other Pencillin-Binding Proteins in Lysis of Escherichia coli by some Beta-Lactam Antibiotics Alone and in Synergistic Lytic Effect of Amdinocillin (Mecillinam)," ANTIMICROBIAL AGENTS & CHEMOTHERAPY 30:906-912 (1986).
	90	Hiasa, H. and Marians, K.J., "Initiation of Bidirectional Replication at the Chromosomal Origin is Directed by the Interaction Between Helicase and primase J. BIOL. CHEM. 274:27244-27248 (1999).
	91	Holzmayer, T.A., et al., "Isolation of Dominant Negative Mutants and Inhibitory Antisense RNA Sequences by Expression Selection of Random DNA Fragments," NUCLEIC ACIDS RES. 20(4): 711-717 (Feb. 25, 1992).
	92	San Martin, C., et al., "Three-Dimensional Reconstructions from Cryoelectron Microscopy Images Reveal an Initimate Complex Between Helicase DnaB and its Loading Partner DnaC," STRUCTURE 6:501-9 (1998).
		Smith, C.E., et al., "Assessment of the Synergistic Interactions of Levofloxacin and Ampicillin Against Enterococcus Faecium by the Checkerboard Agar Dilution and Time-Kill Methods," DIAGNOS. MICROBIOL. INFECT. DISEASE 27:85-92 (1997).
	94	Sutton, M.D., et al, "Escherichia coli DnaA Protein. The N-Terminal Domain and Loading of DnaB Helicase at the E. coli Chromosomal," J. BIOL. CHEM. 273:34255-62 (1998).
	95	Wechsler, J.A. and Gross, J.D., "Escherichia coli Mutants Temperature-Sensitive for DNA Synthesis," MOL. GEN. GENETICS 113:273-284 (1971)
	96	Yinduo Ji, et al., "Regulated Antisense RNA Eliminates Alpha-Toxin Virulence in Staphylococcus Aureus Infection," J. BACTERIOLOGY 181(21): 6585-6590 (November 1999).
	97	Post et al., Nucleotide Sequence of the Ribosomal Protein Gene Cluster Adjacent to the Gene for RNA Polymerase Subunit Beta in Escherichia Coli*, Proceedings of the National Academy of Sciences of the USA, NY, NY vol.76, no. 4, (1979) pgs. 1697-1701.

S:\DOCS\DOH\DOH-5835.DOC 072301

EXAMINER

DATE CONSIDERED

1.7.63

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

A CONTRACTOR OF THE PARTY OF TH	tates in 1		
OIPE		SHEE	T 1 OF 3
3AN 5 3 2002	APPLICATION NO. 09/912,020		
	<b>5</b> .		
APPLICANT Zyskind, et al.		CH CE	JA
FILING DATE July 23, 2001	GROUP 1631	N N	ر د

	·			U.S. PATENT DOCUMENTS			0/2900
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
$\bigcirc$	1	5,082,76?	1/21/92	Hatfield, et al.			
	2	5,142,047	8/25/92	Summerton, et al.			
	3	5,405,775	4/11/95	Inouye, et al.			
	4	5,463,564	10/31/95	Agrafiotis, et al.			
	5	5,574,656	11/12/96	Agrafiotis, et al.			
	6	5,612,180	03/18/97	Brown, et al.			
	7	5,639,603	06/17/97	Dower, et al.			
	8	5,684,711	11/4/97	Agrafiotis, et al.			
	9	5,807,522	9/15/98	Brown, et al.			
	10	5,972,708	10/26/99	Sherratt, et al.			
	11	6,139,817	10/31/00	Palmer, et al.			
	12	6,248,525 B1	06/19/01	Nilsen			
V	13	6,303,115 B1	10/16/01	Natsoulis			

					FOREIGN PATENT DOCUMENTS				
EXAMINER			DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	_ATION
INITI	AL			}				YES	NO
	,	14	WO 95/02823	01/26/95	РСТ				
	•	15	WO 96/17951	06/13/96	PCT		-		
$\exists$	4	16	WO 99/33871	07/8/99	PCT				
	<b></b>	17	WO 99/54728	10/28/99	PCT			:	
	•	18	WO 01/09164 A2	02/08/01	PCT				
	ì	19	WO 01/11081 A2	02/15/01	PCT				
	<u>,</u>	20	WO 01/34809 A2	05/17/01	PCT				-
1)	,	21	WO 01/49775 A2	07/12/01	РСТ				

EXAMINER

DATE CONSIDERED

1.7.63

SH		

,	SUPPLE	S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. 09/912,020
		PLICANT / IAN 0 3 2002	APPLICANT  Zyskind, et al.	
	(USE SEVERAL SHE	ETS IF NECESSARY)	FILING DATE July 23, 2001	GROUP 1631

EXAMIN INITIA			OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
$\overline{\bigcirc}$	١	22	Almarsson, et al. 1993. Peptide nucleic acid (PNA) conformation and polymorphism in PNA-DNA and PNA-RNA hybrids. <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 90:9542-9546.
7		23	Altschul, et al. 1990. Basic local alignment search tool. J. Mol. Biol., 215:403-10.
$\neg T$	(	24	Altschul, et al. 1997. Capped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acid Res., 25(17): 3389-3402.
T		25	Arigoni, et al. 1998. A genome-based approach for the identification of essential bacterial genes. Nature Biotechnology, 16: 851-856.
	ı	26	Ausubel, et al. (Eds.). 1997. Current Protocols in Molecular Biology, Vol. 1, Unit 1.8.1-1.8.10. John Wiley & Sons, Inc.
6		27	Basu, et al. 1997. Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconjugate Chem., 8:481-488.
		28	Bentin, et al. 1996. Enhanced peptide nucleic acid binding to supercoiled DNA: Possible implications for DNA "breathing" dynamics. Biochemistry, 35:8863-8869.
	١.	29	Cao, et al. 1993. Expression and functional analysis of steroid receptor fragments secreted from Staphylococcus aureus. J. Steroid Biochem Molec. Biol., 44(1):1-11.
	,	30	Cotrim, et al. 1999. Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in <i>Leishmania</i> by overexpression/selection. Journal of Biological Chemistry, 274(53):37723-37730.
	,	31	Demidov, et al. 1995. Kinetics and mechanism of polyamide ("peptide") nucleic acid binding to duplex DNA. Proc. Natl. Acad. Sci. U.S.A., 92:2637-2641.
		32	Demidov, et al. 1993. Sequence selective double strand DNA cleavage by Peptide Nucleic Acid (PNA) targeting using nuclease S1. Nucl. Acids. Res., 21(9):2103-2107.
		33	Demidov, et al. 1994. Stability of peptide nucleic acids in human serum and cellular extracts. Biochem. Pharm., 48(6):1010-1313.
	,	34	Egholm, et al. 1995. Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA. Nucleic Acids Res., 23(2):217-222.
		35	Egholm, et al. 1993. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature, 365:566-568.
1.	,	36	Egholm, et al. 1992. Recognition of Guanine and Adenine in DNA by Cytosine and Thymine Containing Peptide Nucleic Acids (PNA). J. Am. Chem. Soc., 114(24):9677-9678.
$\neg$	,	37	Engvall, E. 1980. Enzyme Immunoassay ELISA and EMIT. Meth. Enzymol., 70:419-439.
	<b>£</b> 1	38	Etzold, et al. 1993. Sequence Retrieval System (SRS). SRS-An indexing and retrieval tool for flat file data libraries. Comput. Appl. Biosci. 9(1):49-57.
	,	39	Gallop, et al. 1994. Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries. <i>Journal of Medicinal Chemistry</i> , 37(9):1233-1251.
	٠	40	Griffin, et al. 1989. Recognition of Thymine Adenine Base Pairs by Guanine in a Pyrimidine Triple Helix Motif. Science, 245:967-971.
		41	Griffith, et al. Single and bis peptide nucleic acids as triplexing agents: Binding and Stoichiometry. 1995. J. Am. Chem. Soc., 117:831-832.
	(	42	Hamilton, et al. 1989. New method for generating deletions and gene replacements in Escherichia coli. J. Bacteriol., 171(9):4617-4622.
		43	Hanvey, et al. 1992. Antisense and antigene properties of peptide nucleic acids. Science, 258:1481-1484.
	$\lceil \cdot \rceil$	44	Hensel, et al. 1995. Simultaneous identification of bacterial virulence genes by negative selection. Science, 269:400-403.
	[.	45	Hirschman, et al. 1996. Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus. <i>J. Investig. Med.</i> , 44(6):347-351.
	,	46	Ho, et al. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene, 77:51-59.
	,	47	Horton, et al. 1989. Engineering hybrid genes without the use of restriction enzymes: Gene splicing by overlap extension. Gene, 77:61-68.
		48	Huerta, et al. 1998. RegulonDB: A database on transcriptional regulation in Escherichia coli. Nucl. Acids Res., 26(1):55-59.
	/	49	Kohler, et al. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256:495-497.
V		50	Krause, et al. 1997. Complexes at the replication origin of Bacillus subtilis with homologous and heterologous dnaA protein. J. Mol. Biol., 274:365-380.

EXAMINER DATE CONSIDERED 1. 7.63

Q.	н	E	Г3	١E	-

		3.122,733.7
FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. 09/912,020
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT JAN 0 3 2002	<b>E</b>	
JAN 6 5 ZOUZ	APPLICANT	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE	GROUP
TRADENI OF	July 23, 2001	1631

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
J   +	51	Le Good, et al. 1998. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science, 281:2042-2045.
١.	52	Link, et al. 1997. Methods for Generating Precise Deletions and Insertions in the Genome of Wild-Type Escherichia coli: Application to Open Reading Frame Characterization. J. Bacteriol., 179(20):6228-6237.
$\int$	53	Margolis, et al. 2000. Peptide Deformylase in Staphylococcus aureus: Resistance to Inhibition is Mediated by Mutations in the Formyltransferase Gene. Antimicrobial Agents and Chemotherapy, 44(7):1825-1831.
1,	54	Matsukura, et al. 1988. Synthesis of phosphorothicate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV). Gene, 72:343.
<u> </u>	55	Mollegaard, et al. 1994. Peptide nucleic acid DNA strand displacement loops as artificial transcription promoters. Proc. Natl. Acad. Sci. U.S.A., 91:3892-3895.
c	56	Nielsen, et al. 1991. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science, 254:1497-1500.
	57	Nielsen, et al. 1993. Sequence specific inhibition of DNA restriction enzyme cleavage by PNA. Nucl. Acids. Res., 21(2):197-200.
•	58	Nielsen, et al. 1994. Sequence-specific transcription arrest by peptide nucleic acid bound to the DNA template strand. Gene, 149:139-145.
	59	Norton, et al. 1996. Inhibition of human telomerase activity by peptide nucleic acids. Nature Biotechnol., 14:615-619.
	60	Pardridge, et al. 1995. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. U.S.A., 92:5592-5596.
4	61	Pearson, W. R. 1990. Rapid and sensitive sequence comparison with FASTP and FASTA. Methods in Enzymology, 183:63-98.
1	62	Plá, et al. 1990. Cloning and expression of the ponB gene, encoding penicillin-binding protein 1B of Escherichia coli, in heterologous systems. J. Bacterio 172(8):4448-4455.
? .	63	Rossi, et al. 1991. The potential use of catalytic RNAs in therapy of HIV infection and other diseases. Pharmac. Ther., 50:245-254.
	64	Rudd, K. E. 1998. Linkage map of Escherichia coli K-12, edition 10: The physical map. Micro. & Mol. Biol. Rev., 62(3):985-1019.
	65	Schena, et al. 1995. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science, 270:467-470.
,	66	Shalon, et al. 1996. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. <i>Genome Research</i> , 6:639-645.
	67	Tao, et al. 2000. Drug target validation: Lethal infection blocked by inducible peptide. PNAS, 97(2):783-786.
	68	Uhlmann, et al. 1990. Antisense Oligonucleotides: A New Therapeutic Principle. Chemical Reviews, 90(4):543-584.
1.	69	Vaitukaitis, et al. 1971. A method for producing specific antisera with small doses of immunogen. J. Clin. Endocr. Metab., 33:988-991.
V	70	Zhang, et al. 1996. Polar Allele Duplication for Transcriptional analysis of consecutive essential genes: Application to a cluster of Escherichia coli fatty aci biosynthetic genes. J. Bacteriol., 178(12):3614-3620.
/ (	71	Zhang, et al. 2000. Regulated Gene Expression in Staphylococcus aureus for Identifying Conditional Lethal Phenotypes and Antibiotic Mode of Action. Gene, 255:297-305.
/		

S:\DOCS\DOH\DOH-6287.DOC:dmb 120601

1		
EXAMINER	DATE CONSIDERED	1.7.03

			9			Pa	per N	v:5	SHEET 1 OF 2
	FORM PTO-1449  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. ELITRA.001DV1		APPLIC/ 09/912	ATION NO.	MA CELLA
	115	BY APPLICANT	APPLICANT Zyskind, et al.			CACEN	72000		
MAR.		RAL SHEETS IF NECES	SARY)		FILING DATE July 23, 2001		GROUP 1631		~ 100/2300
PATELLA PA	DEMARK				U.S. PATENT DOCUMENTS				
EXAMINER INITIAL		OCUMENT NUMBER	DATE		NAME		CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
(ک	1	6,348,582 B1	02/19/02	Black	k, et al.				
	2	6,348,582	02/19/02	Black	k, et al. (Printout of Sequence Listing)				
								j	

FOREIGN PATENT DOCUMENTS												
DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION						
						YES	NO					
3	EP 0 786 519 A2	07/30/97	EPO									
4	EP 0 786 519 A3	07/30/97	EPO									
5	WO 00/61793	10/19/00	РСТ									
3	WO 01/49721 A2	07/12/01	РСТ									
$\top$												
5	;	EP 0 786 519 A2 EP 0 786 519 A3 WO 00/61793 WO 01/49721 A2	EP 0 786 519 A2 07/30/97 EP 0 786 519 A3 07/30/97 WO 00/61793 10/19/00 WO 01/49721 A2 07/12/01	B EP 0 786 519 A2 07/30/97 EPO B EP 0 786 519 A3 07/30/97 EPO WO 00/61793 10/19/00 PCT WO 01/49721 A2 07/12/01 PCT	B EP 0 786 519 A2 07/30/97 EPO  EP 0 786 519 A3 07/30/97 EPO  WO 00/61793 10/19/00 PCT  WO 01/49721 A2 07/12/01 PCT	EP 0 786 519 A2 07/30/97 EPO  EP 0 786 519 A3 07/30/97 EPO  WO 00/61793 10/19/00 PCT  WO 01/49721 A2 07/12/01 PCT	YES  EP 0 786 519 A2 07/30/97 EPO  EP 0 786 519 A3 07/30/97 EPO  WO 00/61793 10/19/00 PCT  WO 01/49721 A2 07/12/01 PCT					


EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
7	7	Akerley, et al., "A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae," PNAS, 99(2):966-971 (2002).
	8	Blattner, et al., "Escherichia coli K12 MG1655 section 101 of 400 of the complete genome," Database accession no. AE000211, XP002181472.
	9	Blattner, et al., "Escherichia coli K12 MG1655 section 298 of 400 of the complete genome," Database accession no. AE000408, XP002181129.
	10	Blattner, et al., "Escherichia coli K12 MG1655 section 305 of 400 of the complete genome," Database accession no. AE000415, XP002181474.
	11	Blattner, et al., "Escherichia coli K12 MG1655 section 337 of 400 of the complete genome," Database accession no. AE000447, XP002181127.
	12	Blattner, et al., "Hypothetical 79.5 kDa protein in MRCA-PCKA intergenic region (0711)," Database accession no. P45800, XP002181475.
	13	Blattner, et al., "Hypothetical protein YCFS precursor," Database accession no. P75954, XP002181473.
	14	Burland, et al., "60 kDa inner-membrane protein," Database accession no. P25714, XP002181128.
	15	Burland, et al., "E. coli; the region from 81.5 to 84.5 minutes," Database accession no. L10328, XP002181130.
1/	16	Burland, et al., "DNA sequence and analysis of 136 kilobases of the Escherichia coli genome: Organizational symmetry around the origin of replication," Genomics, 16:551-561 (1993).
7/1/	17	Ceretti, et al., "Escherichia coli spc ribosomal protein operon," Database accession no. X01563, XP002181131.
41	18	De Backer, et al., "An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans," Nature Biotechnology, 19:235-241 (2001).

EXAMINER

DATE CONSIDERED

_		FT	. ^	$\sim$	-,
- 5	mr	1	_		

1631



July 23, 2001

	The state of the s
EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)  Lancy, et al., "Nucleotide Sequences of dnaF, the Gene for the Polymerase Subunit of DNA Polymerase III in Salmonella typhimurium and a Variant That
0)	19 Facilitates Growth in the Absence of Another Polymerase Subunit," Journal of Bacteriology, 171(10):5581-5586 (1989).
	Oshima, et al., "A 718-kb DNA Sequence of the Escherichia coli K-12 Genome Corresponding to the 12.7-28.0 min Region on the Linkage Map," DNA Research, 3:137-155 (1996).
	Oshima, et al., "Escherichia coli genomic DNA (25.2-25.6 min)," Database accession no. D90747, XP002181476 (1996).
	Plunkett, et al., "Escherichia coli K-12 chromosomal region from 67.4 to 76.0 minutes," Database accession no. U18997, XP002181132.
B	Plunkett, et al., "Escherichia coli K-12 chromosomal region from 67.4 to 76.0 minutes," Database accession no. U18997, XP002181477.
Ø	·
77.00	
	ı
ŀ	

S:\DOCS\DOH\DOH-6494.DOC:dmb 022102

	1	$\overline{}$				<u> </u>
EXAMINER	1/		_	DATE CONSIDERED	1.7.0	>
	7.7					

PW NO:7

FORMPTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. ELITRA.001DV1

APPLICATION NO. 09/912,020

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS EXECESSARY)

APPLICANT Zyskind, et al.

MAY 1 5 2002

FILING DATE July 23, 2001 GROUP 1634

TECH CENTER 1600/2900

		P	TC AND TO THE TO		U.S. PATENT DOCUM	ENTS			
EXAMINER INITIAL			DOCUMENTALUMBER	DATE	NA	AME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
>		1	5,353,236	10/04/94	Subbiah				
$\neg$		2	5,744,460	04/28/98	Müller, et al.	COPY OF PAPERS ORIGINALLY FILED			
T		3	5,869,604	02/09/99	Rousseau, et al.				
1		a/	6,077,682	06/20/00	Inouye, et al.				
1	eg	5	6,156,526	12/05/00	Boriack-Sjodin, et al.				
7/	1	6	6,277,564	08/21/01	Berlin, et al.				

FOREIGN PATENT DOCUMENTS												
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION						
						YES	NO					
7	WO 98/50555	11/12/98	PCT									
8	WO 99/13893	03/25/99	PCT									
	7 8	7 WO 98/50555	7 WO 98/50555 11/12/98	DOCUMENT NUMBER         DATE         COUNTRY           7         WO 98/50555         11/12/98         PCT	DOCUMENT NUMBER   DATE   COUNTRY   CLASS	DOCUMENT NUMBER         DATE         COUNTRY         CLASS         SUBCLASS           7         WO 98/50555         11/12/98         PCT	DOCUMENT NUMBER   DATE   COUNTRY   CLASS   SUBCLASS   TRANS   YES					

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
/11	9	Ala'Aldeen, et al. 2001. Unveiling of genetic basis of resistance of S aureus to antibiotics. The Lancet, 357(9264):1218-1219
7	10	Appelt, K. 1993. Crystal structures of HIV-1 protease-inhibitor complexes. Perspectives in Drug Discovery and Design. 1 23-48
T	11	Bagby, et al. 1994. Unusual helix-containing Greek keys in development-specific Ca <sup>2+</sup> -binding protein S. <sup>1</sup> H. <sup>15</sup> N, and <sup>13</sup> C assignments and secondary structur determined with the use of multidimensional double and triple resonance heteronuclear NMR spectroscopy. <i>Biochemistry</i> , 33:2409-2421.
	12	Bagby, et al. 1995. Solution structure of the C-terminal core domain of human TFIIB: Similarity to Cyclin A and interaction with TATA-binding protein Cell. 82:857-867.
	13	Balbes, et al. 1994. "A perspective of modern methods in computer-aided drug design." In Lipkowitz, et al., Eds. Reviews in Computational Chemistry V. Chap. 7, pp. 337-379. New York: VCH Publishers.
	14	Brenner, et al. 2000. Salmonella nomenclature. Journal of Clinical Microbiology, 38(7):2465-2467.
	15	Brunschwig, et al. 1992. A two-component T7 system for the overexpression of genes in <i>Pseudomonas aeruginosa. Gene</i> , 111:35-41.
	16	Bugg, et al. 1993. Drugs by design: Structure-based design, an innovative approach to developing drugs, has recently spawned many promising therapeutic agents, including several now inhuman trials for treating AIDS, cancer and other diseases. Scientific American, Dec.:92-98.
	17	Clore, et al. 1987. Three-dimensional structure of potato carboxypeptidase inhibitor in solution: A study using nuclear magnetic resonance, distance geometry, and restrained molecular dynamics. <i>Biochemistry</i> , 26:8012-8023.
	18	Crosa, et al. 1973. Molécular relationships among the Salmonelleae. J. Bacteriol, 115(1):307-315.
1	19	Cwirla, et al. 1990. Peptides on phage: A vast library of peptides for identifying ligands. Proc. Natl. Acad. Sci. USA, 87:6378-6382.
$\top$	20	Devlin, et al. 1990. Random peptide libraries: A source of specific protein binding molecules. Science, 249:404-406.
1	21	Edwards, B. H. 1999. Salmonella and Shigella species. Clinics Lab. Med., 19(3):469-487.
1	22	Erickson, J. W. 1993. Design and structure of symmetry-based inhibitors of HIV-1 protease. Perspectives in Drug Discovery and Design. 1:109-128.
W/	23	Good, et al. 1998. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA, Nature Biotechnology, 16:355-358

EXAMINER

DATE CONSIDERED

1.7.03

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. ELITRA.001DV1

APPLICATION NO 09/912,020

#### COPY OF PAPERS ORIGINALLY FILED

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF DECESSARY)

APPLICANT Zyskind, et al.

MAY 1 5 2002

FILING DATE July 23, 2001 GROUP 1634

TECH CENTER 1600/2900

		July 23, 2001 1634 TECH CENTER 1600/4
		MAY 1 3 2007 E
EXAMINEF INITIAL	₹	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
1	24	Hare, et al 2001 Cenetic footprinting in bacteria. J. Bacteriol., 183(5):1694-1706.
1	25	Huycke, et al. 1998. Multiple-drug resistant enterococci: The nature of the problem and an agenda for the future. Emerging Infectious Diseases. 4(2):239-249.
	26	Israelsen, et al. 1995. Cloning and partial characterization of regulated promoters from Lactococcus lactis Tn917-lacZ integrants with the new promoter probe vector, pAK80, Applied and Environmental Microbiology, 61(7):2540-2547.
	27	Kreiswirth, et al. 1983. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature, 305:709-712.
	28	Kuroda, et al. 2001. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. The Lancet, 357(9264):1225-1240.
	29	Lam, et al. 1994. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science, 263:380-384.
	30	Leboeuf, et al. 2000. Characterization of the ccpA gene of Enterococcus faecalis: Identification of starvation-inducible proteins regulated by CcpA.  J. Bacteriology, 182(20):5799-5806.
	31	Marrone, et al. 2000. Discovering high-affinity ligands from the computationally predicted structures and affinities of small molecules bound to a target: A virtual screening approach. Perspectives in Drug Discovery and Design, 20:209-230.
	32	Mestres, et al. 2000. Similarity versus docking in 3D virtual screening. Perspectives in Drug Discovery and Design, 20:191-207
	33	Mojumdar, et al. 1988. Characterization of the tetracycline resistance gene of plasmid pT181 of Staphylococcus aureus. J. Bacteriology, 170(12):5522-5528.
	34	Morrissey, et al. 2000. Molecular Cloning and Analysis of a Putative Siderophore ABC Transporter from Staphylococcus aureus. Infection and Immunity. 68(11):6281-6288.
	35	Moszer, et al. 1995. SubtiList: A relational database for the Bacillus subtilis genome. Microbiology, 141:261-268.
	36	Moszer, I. 1998. The complete genome of Bacillus subtilis: From sequence annotation to data management and analysis. FEBS Letters, 430:28-36.
	37	MRSA genomc unravelled. Abstract. 2000. The Lancet, 357(9264).
	38	Nallapareddy, et al. 2000. Enterococcus faecalis adhesin, ace, mediates attachment to extracellular matrix proteins collagen type IV and laminin as well as collagen type I. Infect. Immun., 68(9):5218-5224.
	39	Neidhardt, F. C. (Ed.). 1996. Escherichia coli and Salmonella: Cellular and molecular biology, 2nd Ed., Vol. 2, pp. 2269-2271. Washington, D.C.: ASM Press.
	40	Schnappinger, et al. 1995. Extracellular expression of native human anti-lysozyme fragments in Staphylococcus carnosus. FEMS Microbiol. Let., 129:121-127.
	41	Scott, et al. 1990. Searching for peptide ligands with an epitope library. Science, 249:386-390.
	42	Shuker, et al. 1996. Discovering high-affinity ligands for proteins: SAR by NMR. Science, 274:1531-1534.
	43	Suh, et al. 1995. Genetic and transcriptional organization of the Bacillus subtilis spc-alpha region. Database accession no. L47971 (ID: BSRPLP), XP002190118.
	44	Suh, et al. 1996. Genetic and transcriptional organization of the Bacillus subtilis spc-alpha region. Gene, 169:17-23.
	45	Tatusov, et al. 2000. The COG database: A tool for genome-scale analysis of protein functions and evolution. Nucleic Acids Research, 28(1):33-36.
	46	Van Delden, et al. 1998. Cell-to-cell signaling and Pseudomonas aeruginosa infections. Emerging Infectious Diseases, 4(4):551-560.
	47	Wagner, et al. 1987. Protein structures in solution by nuclear magnetic resonance and distance geometry: The polypeptide fold of the basic pancreatic trypsin inhibitor determined using two different algorithms, DISGEO and DISMAN. J. Mol. Biol., 196:611-639.
	48	Wallis, et al. 2000. Molecular basis of Salmonella-induced enteritis. Molec. Microb., 36(5):997-1005.
	<b>1</b> 9	Wlodawer, et al. 1993. Structure-based inhibitors of HIV-1 protease. Annu Rev. Biochem., 62:543-585
	50	Wong, et al. 2000. Genetic footprinting with mariner-based transposition in Pseudomonas aeruginosa. PNAS, 97(18):10191-10196.
(V	51	Wüthrich, et al. 1983. Pseudo-structures for the 20 common amino acids for use in studies of protein conformations by measurements of intramolecular proton-proton distance constraints with nuclear magnetic resonance. J. Mol. Biol., 169:949-961.
M	52	Xia, et al. 1999. Rapid method for the identification of essential genes in Staphylococcus aureus. Plasmid, 42:144-149.

S:\D|\CS\D\OH\D\H-6640\DOC:dmb - 043002

EXAMINER

DATE CONSIDERED

1.03

					Paper N	SHEET 1 OF			
FORMP	TO-1449 U.S. DEPARTMEN PATENT AND TE	NT MMERC		APPLICA 09/912	TION NO. ,020				
E JCKUF	SUPPLEMENTAL RMATION DISCLOSURE STAT				RECEIVE				
3 8 MIL	BY APPLICANT		APPLICANT Zyskind, et al.	JUL 0 2 200					
·	SE SEVERAL SHEETS IF NECES	SARY)	FILING DATE July 23, 2001	GROUP 1635	TECH	CENTER 1600/			
गत्रा ६ 🥕			U.S. PATENT DOCUMENTS	<del></del>					
		<del></del>	U.S. PATENT BOSOMENTO						
XAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)			
	6,228,579 B1	05/08/01 Z	yskind, et al.						
2	6,228,588 B1	05/08/01 B	enton, et al.		COPY ORIGIN	OF PAPERS ALLY FILED			
		1		<b>-</b>					
			FOREIGN PATENT DOCUMENTS						
KAMINER	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
INITIAL						YES NO			
			· - · · · · · · · · · · · · · · ·			<u> </u>			
XAMINER		OTHER DOCUME	NTS (INCLUDING AUTHOR, TITLE, DATE, PERTINEN	IT PAGES, ETC	C.)				
INITIAL /	Good at al. 1998 Inhibition of tr	anslation and bact	erial growth by peptide nucleic acid targeted to ribosom	nal RNA. Proc.	Natl. Acad. Sc	i. USA. 95:2073-2076.			
<b>1</b> 3	G000, et al. 1990. Illinoidori oi d	ansienon and beck	and grown by popular masses as a sgreat to masses.						
1	1								
	DOH-6821.DOC:dmb								
DOCS\DOH\\2402	DOH-6821.DOC:dmb		DATE CONSIDERED '						

· •	··-					Paper N.	:9	SHEET 1 OI		
a E	M PTO-1449	JPPLEMENTAL	RADEMARK OFFIC			ATION NO.		EIV		
	્રેફુ <sub>ક</sub> Β	DISCLOSURE STAT		APPLICANT Zyskind, et al.		SEP 1 3 200				
EP 1.0 &	٥	L SHEETS IF NECES	SARY)	FILING DATE July 23, 2001	GROUP 1635	TEC	1 CENT!	R 1600		
ENT & TRA										
	/			U.S. PATENT DOCUMENTS		<u> </u>				
EXAMINER INITIAL	DOG	CUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		G DATE ROPRIATE)		
7/_	1 US	2002/0058260 A1	05/16/02 Zy	skind, et al.		<del> </del>				
<u> </u>						COPY OF ORIGINA				
·					-		-	<del></del>		
				FOREIGN PATENT DOCUMENTS		1				
XAMINER	DOO	CUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
INITIAL							YES	NO		
XAMINER			OTHER DOCUMEN	ITS (INCLUDING AUTHOR, TITLE, DA	ATE DEDTINENT DAGES ET	~ 1				
INITIAL			OTTER BOOME	TO (MOLOBINO AO MON, MEL, DA	TIC, TENTILETT FACES, EN			···		
								-		
			· · · · · · · · · · · · · · · · · ·							
	_					<del></del>				
			·	<del></del>	-					
						<del> </del>		<del></del>		
		<u>.</u>								
		<del></del>								
DOCS\DOI	<del></del>	OOC:dmb								
KAMINER	7			DATE CONSIDER	RED 1.7.1	3				
	INITED IS CIT.	ATION CONSIDERED	, WHETHER OR N	IOT CITATION IS IN CONFORMAN	ICE WITH MPEP 609: DRAW	LINE THROI	ICH CITATI			

FOR		<del> </del>		. ,				S	HEET 1
	м рто-		NT OF COMMER RADEMARK OFF		ATTY. DOCKET NO. ELITRA.001DV1	APPLIC 09/912	ATION NO. 2,020		
		SUPPLEMENTAL MATION DISCLOSURE STAT	EMENT			<u></u>			
BY APPLICANT  BY APPLICANT  BY APPLICANT  BY APPLICANT					APPLICANT Zyskind, et al.				
					FILING DATE July 23, 2001	GROUP 1635			
ENT & TR		<u> </u>			U.S. PATENT DOCUMENTS		· ·	-	•
A TR	AU		· · · · · ·		, , , , , , , , , , , , , , , , , , , ,	<del></del>	ı	<del></del>	<del></del>
KAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING (IF APPR	DATE OPRIATE
	1	5,874,281	02/23/99	Datta	gupta, et al.				
	2	5,874,567	02/23/99	Smith	1				
					The second secon				
						1			
			,	FO	REIGN PATENT DOCUMENTS				<del></del>
AMINER		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION	
VITIAL								YES	NO
	3	WO 95/29254	11/02/95	PCT					
			_						
	<del>├</del>		1						
			<u> </u>						
MINER			OTHER DOCUM	IENTO	(INCLUDING AUTHOR TITLE DATE DEPTINENT	24058 57			
			OTHER DOCUM	IENTS	(INCLUDING AUTHOR, TITLE, DATE, PERTINENT I	PAGES, ETC	C.)		<del></del>
			OTHER DOCUM	IENTS	(INCLUDING AUTHOR, TITLE, DATE, PERTINENT I	PAGES, ETC	5.)		
			OTHER DOCUM	IENTS	(INCLUDING AUTHOR, TITLE, DATE, PERTINENT I	PAGES, ETC	2.)		
			OTHER DOCUM	IENTS	(INCLUDING AUTHOR, TITLE, DATE, PERTINENT I	PAGES, ETC	2.)		
			OTHER DOCUM	IENTS	(INCLUDING AUTHOR, TITLE, DATE, PERTINENT I	PAGES, ETC	2.)		
			OTHER DOCUM	IENTS	(INCLUDING AUTHOR, TITLE, DATE, PERTINENT I	PAGES, ETC	D.)		
AMINER NITIAL			OTHER DOCUM	IENTS	(INCLUDING AUTHOR, TITLE, DATE, PERTINENT I	PAGES, ETC	C.)		
			OTHER DOCUM	IENTS	(INCLUDING AUTHOR, TITLE, DATE, PERTINENT I	PAGES, ETC	2.)		
			OTHER DOCUM	IENTS	(INCLUDING AUTHOR, TITLE, DATE, PERTINENT I				
			OTHER DOCUM	ENTS	(INCLUDING AUTHOR, TITLE, DATE, PERTINENT I			CEIV	E
			OTHER DOCUM	IENTS	(INCLUDING AUTHOR, TITLE, DATE, PERTINENT I		RECH (	CEN	7EC 2002

\*EXAMINER: INVIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

DATE CONSIDERED

EXAMINE R